Chimeric antigen receptor T cell: A cancer immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Targeted drug therapy, including tyrosine kinase inhibitors and HER2 inhibitors, has advanced cancer treatment.
• Adoptive cell transfer (ACT) is a developing immunotherapy approach.
• Chimeric antigen receptors T cell (CAR-T) therapy represents the most advanced form of ACT.

Purpose of the Study:

• To review the advancements in CAR-T cell therapy for cancer treatment.
• To discuss approved CAR-T drugs targeting CD19 and their applications.
• To highlight challenges and future directions in CAR-T therapy.

Main Methods:

• CAR-T therapy involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs).
• These modified T cells are expanded and then infused back into the patient to target cancer cells.
• The review discusses specific approved CAR-T drugs and their mechanisms.

Main Results:

• Four CAR-T drugs targeting CD19 have been approved: Tisagenlecleucel, Axicabtagene Ciloleucel, Brexucabtagene Ciloleucel, and Lisocabtagene Maraleucel.
• CAR-T therapy is approved for Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, and lymphoma.
• CAR-T cell persistence and safety are key factors influencing effectiveness and broader application.

Conclusions:

• CAR-T therapy has shown significant clinical advancement in treating certain hematological malignancies.
• Further research is exploring new targets like growth factor receptors and cluster of differentiation for enhanced immunotherapy.
• Addressing CAR-T cell persistence and safety concerns is crucial for expanding its use in cancer patients.